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Symposium I: Consequences of obesity and overweight during pregnancy
Improving pregnancy outcome in obese women
Fiona C. Denison* and Carolyn Chiswick
MRC/University of Edinburgh Centre for Reproductive Health, The Queen’s Medical Research Institute, 47 Little France
Crescent, Edinburgh EH16 4TJ, UK
The global pandemic of maternal obesity presents a major challenge for healthcare providers,
and has significant short- and long-term implications for both maternal and fetal health. Cur-
rently, the evidence-base underpinning many of the interventions either currently in use or
recommended to improve pregnancy outcome in obese women is limited. The nature and
timing of these interventions vary widely, ranging from simple advice to more intensive dietary
and exercise programmes, cognitive behavioural therapy and drug trials. In addition, a growing
number of very severely obese women now enter pregnancy having had surgical interventions.
Although surgical interventions such as gastric bypass or banding may be associated with
improved pregnancy outcomes, these women have particular nutritional requirements, which
need to be addressed to optimise pregnancy outcome. Until the outcomes of ongoing current
trials are reported and provide a firm evidence base on which to base future intervention
strategies and guide evidence based care for obese pregnant women, pregnancy outcome is best
optimised by high-risk antenatal care delivered by healthcare providers who are experienced in
supporting these high-risk women.
Obesity: Pregnancy: Interventions
Obesity is now the commonest antenatal co-morbidity
and affects one in five pregnant women in the UK. The
exponential rise in obesity across the developed world has
prompted the World Health Organisation to describe it as
one of the most important global health problems today(1).
Maternal obesity is associated with increased morbidity
and mortality for both mother and offspring. Antenatal
risks include gestational diabetes, hypertensive disorders
including pre-eclampsia and thromboembolic complica-
tions(2–4). In the UK, the most recent Confidential Enquiry
into Maternal and Child Health reported that 78% of
women who died of a thromboembolism were overweight
or obese (BMI>25 kg/m2)(5). Peripartum, women are more
likely to face induction of labour, operative delivery and
postpartum haemorrhage(3,6). High pregravid BMI and
excessive gestational weight gain are also important
predictors of short-term postpartum morbidity(7) and
higher postpartum weight retention(8) with the latter being
associated with increased risks for future pregnancy and
lifelong obesity(9). Offspring of obese mothers tend to be
large for gestational age at birth and are at higher risk of
congenital anomaly, late fetal death and admission to the
neonatal unit. Maternal obesity also increases the lifetime
risk of obesity in offspring and a tendency to develop
metabolic syndrome in childhood and adolescence(10),
thus perpetuating the cycle of obesity and its adverse
consequences into the next generation. There is, therefore,
an urgent need to develop interventions that improve
pregnancy outcomes and long-term health for both mother
and baby. This review will summarise the current evidence
base for interventions aimed at improving pregnancy
outcome for obese women.
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The following key principles inform design, delivery and
effectiveness of interventions aimed at improving preg-
nancy outcome for obese women. These will be outlined
before considering the evidence for specific interventions.
What is (are) the aim(s) of the intervention and
who is it aimed at?
Does the intervention target direct (e.g. maternal weight
gain, dietary and/or cardiovascular fitness) or indirect (e.g.
pre-eclampsia, gestational diabetes, caesarean section, fetal
macrosomia and/or offspring obesity) consequences of
obesity?
Many trials use limitation of maternal weight gain dur-
ing pregnancy as their primary outcome(11). Maternal
obesity is a significant determinant of gestational weight
gain, which if excessive is an independent predictor of
adverse maternal and fetal outcome for pregnancy, with
consequent lifelong health implications. However, the
optimal gestational weight gain for women of different
BMI categories remains to be established. Although
guidelines, such as those generated by the Institute of
Medicine(12), now provide recommendations for gesta-
tional weight gain, dependent on maternal weight or BMI
at antenatal booking, there are no recommendations to
inform weight gain for very severely obese women with a
BMI>40 kg/m2, who comprise an increasing proportion of
the antenatal population. In addition, guidelines are only
relevant for the population for whom they are generated.
For example, the Institute of Medicine guidelines are
intended for use in the USA. Although they may be rele-
vant to other developed countries, they are not applicable
to other countries where the antenatal population are either
heavier or lighter, have different demographics or ethnic
origin to women in the USA. If gestational weight gain is
being used as a trial outcome, it is therefore, important
that guidelines used are relevant to the study population.
Furthermore, whether limiting maternal weight gain actu-
ally improves maternal and infant health remains to be
established due to the lack of high-quality information
from randomised trials(11).
Intervention trials in pregnancy are also complicated
because any intervention given during pregnancy affects
both mother and fetus. Importantly, the outcomes for
mother and fetus may differ and evolve over time. For
example, the ORACLEII (Overview of the Role of Anti-
biotics in the Curtailment of Labour and Early delivery)
trial randomised women at risk of preterm labour, with
intact fetal membranes and no evidence of infection to
receive erythromycin, co-amoxiclav or placebo daily until
delivery. There was no difference in the primary outcome
(composite of neonatal death, chronic lung disease or
major cerebral abnormality on ultrasonography) before
discharge from hospital between study groups(13). How-
ever, when babies were followed up at age 7, prescription
of erythromycin for women in spontaneous preterm labour
with intact membranes was associated with an increase in
functional impairment among their children; and the risk of
cerebral palsy was increased by either antibiotic, although
the overall risk of this condition was low(14).
Thus, for any trial involving pregnancy, it is important
that the primary outcomes are appropriate and considera-
tion should be given for long-term follow-up studies for
both mother and offspring to ensure that adverse long-term
health outcomes are not missed.
What is the timing duration and intensity of
the intervention?
Study design varies considerably, with some interventions
being delivered before, some during and others after
pregnancy. This makes comparison between studies diffi-
cult. For example, if the aim of the study is to reduce the
incidence of a disease such as pre-eclampsia that only
occurs during pregnancy, the intervention may be limited
to the duration of pregnancy. However, for lifestyle inter-
ventions, which aim to alter maternal and/or offspring
behaviour, the interventions may be longer term, poten-
tially spanning the lifetime of both mother and offspring.
Similarly, the intensity of an intervention may vary con-
siderably, particularly if the intervention is aimed at
changing maternal behaviour. For example, an exercise
intervention may range from a single group session to a
structured programme of exercises with goal setting
delivered on a one-to-one basis by an exercise or personal
trainer.
Lifestyle interventions
Pregnancy is a period in a woman’s reproductive life when
she may be more motivated to undertake lifestyle changes,
such as altering the quantity or quality of the food that
she eats or undertaking exercise. Below, the evidence for
dietary, exercise and psychological interventions in
improving pregnancy outcome are considered individually,
before assessing the evidence for complex interventions
involving all three lifestyle interventions.
Dietary advice
General dietary advice is part of routine antenatal care and
is delivered by a wide range of health and allied health
professionals. However, most of the written information
currently available is generic, and is neither tailored to the
individual needs of women nor takes into account their
pre-pregnancy BMI. For example, the dietary information,
food knowledge and nutritional intake required by a lean
woman is very different from that required by an over-
weight or obese pregnant woman, who is likely to have a
more unbalanced diet, to be consuming larger portion sizes
and for whom excessive weight gain in pregnancy is to be
avoided. However, whether tailored dietary advice alone
translates to quantifiable changes in maternal behaviour,
such as improving the quality of nutritional intake or
pregnancy outcomes is not yet proven(11). In addition, there
is evidence that obese women are often unaware of the risk
that obesity poses to their pregnancy and have a distorted
view of the nutritional quality and quantity of the food they





















consume(15). With regard to food quantity, it is important
to educate women about appropriate energy intake and
dispel the widely held myth that she must ‘eat for two’.
In fact no extra energy intake is required in the first two
trimesters of pregnancy, and only an extra energy intake of
837J (200 calories) per d in the third trimester(16).
There is also a paucity of evidence about the beneficial
health effects (or otherwise) of specific micronutrient
supplementation in obese women. Exposure of the skin
to sunlight is the main source of vitamin D synthesis. In
countries where there is limited sunlight of appropriate
wavelength, for example, the UK, or where, for cultural
reasons skin is covered thus preventing exposure to sun-
light, skin exposure alone may not be sufficient to achieve
optimal vitamin D status for pregnancy(17). This deficiency
is accentuated in obesity. Women with a BMI>30 kg/m2
are at increased risk of vitamin D deficiency compared
to healthy weight controls(18), possibly because of seques-
tering of vitamin D in adipose tissue, with high pre-
pregnancy BMI being associated with low serum vitamin
D levels during pregnancy(19). The UK Royal College
of Obstetricians and Gynaecologists recommend vitamin
D supplementation of 10 mg/d for women with a
BMI>30 kg/m2 (Centre for Maternal and Child Enquiries/
Royal College of Obstetricians and Gynaecologists joint
guideline). However, there are no randomised clinical trials
to support these recommendations, and limited evidence
regarding the safety of higher dose antenatal vitamin D
regimes(20).
The current recommendation by the Royal College of
Obstetricians and Gynaecologists in the UK(21) that obese
women should take a high dose pre-conceptual folic acid to
reduce their increased risk of neural tube defects is simi-
larly based on a paucity of evidence. In the general obste-
tric population, the use of peri-conceptual folic acid to
reduce the risk of neural tube defects is well established.
Thus, all women trying to conceive are encouraged to
take peri-conceptual folic acid at the standard 400mg/d
dose(22). A higher dose of folate supplementation is re-
commended for those women identified as being at higher
risk, for example, women with a previously affected preg-
nancy. In these high-risk women, this higher dose of folic
acid reduces the risk of having a fetus affected by a neural
tube defect in a subsequent pregnancy(23). However, the
protective effects of peri-conceptual folic acid do not
appear to benefit obese women. Following introduction of
flour fortification with folic acid in women with increased
BMI, a Canadian study demonstrated no benefit, in
terms of reduction in incidence of neural tube defects(24).
Whether higher dose supplementation of folic acid effects
a reduction in risk of neural tube defects in obese women
remains to be established in clinical trials, thus current
recommendations should be viewed with caution.
Exercise
In non-pregnant individuals, regular exercise is associated
with maintenance of healthy weight and improved
cardiovascular fitness. Many women who are accustomed
to regular exercise outside pregnancy, therefore, wish to
continue exercising during pregnancy. In healthy pregnant
women, regular aerobic exercise during pregnancy main-
tains or improves physical fitness with studies demon-
strating improvements in functional aerobic capacity and
cardiorespiratory capacity(25–28). Short bouts of maternal
exercise are also associated with fetal physiological
responses, in particular, an increase in fetal heart rate(29,30).
Whether these beneficial effects extend to obese pregnant
women is not known.
In non-pregnant women, the benefits of exercise extend
beyond weight maintenance, to include lowering of blood
pressure(31), improved insulin sensitivity(32), reduced risk
of CHD(33) and Type II diabetes(34) and improved psy-
chological well being. Whether these beneficial effects
extend to pregnancy and are associated with improved
maternal and offspring health outcomes are, however, less
clear. A recent Cochrane review that evaluated the role
of exercise or other physical activity in lean women to
prevent pre-eclampsia and its complications concluded that
‘There is insufficient evidence for reliable conclusions
about the effects of exercise on prevention of pre-
eclampsia and its complications’(35). In obese women,
although some studies suggest that regular exercise either
before or during pregnancy may improve cardiovascular
fitness(36), reduce the risk of gestational diabetes(37) and
attenuate the gestational increase in blood pressure in
obese women(38), other studies are not supportive. Simi-
larly, whether regular exercise influences the rate of other
pregnancy complications such as preterm birth is not clear.
Although a recent Cochrane review demonstrated that
increasing exercise in non-obese sedentary women does
not result in a clinically important shortening of gestation
(mean difference+0.10, 95% CI - 0.11, +0.30 weeks), it
also showed that increasing exercise was associated with a
non-significant increase in the risk of preterm birth (risk
ratio 1.82, 95% CI 0.35, 9.57)28. The optimal combination
of exercise with/without other lifestyle interventions to
improve clinical outcome, therefore, remains to be estab-
lished by adequately powered clinical trials.
Psychological interventions
Cognitive behavioural therapy for obesity uses cognitive
restructuring, stimulus control and self-monitoring to pro-
mote weight loss(39). Cognitive restructuring is based on
the theory that behaviour can be controlled by conscious
thought. Stimulus control techniques teach patients to
understand, control and potentially avoid triggers asso-
ciated with eating and self-monitoring, teaching patients to
become aware of their eating patterns, and to keep records
of their food intake to enable them to assess energy
intake(40). Studies consistently demonstrate that interven-
tions based on the theory of cognitive behavioural therapy
increase the desire to control weight, boost self-esteem,
and increase self-efficacy and satisfaction with body areas
and appearance(41). However, although behavioural inter-
ventions are generally effective in promoting weight loss
in the short term, they are less effective in maintaining
weight loss in the long term(42). There are no studies using





















cognitive behavioural approaches as a method of control-
ling weight in pregnancy.
Complex interventions
Complex intervention clinical trials, comprising dietary
advice, exercise and psychological interventions are widely
used as a method of effecting weight reduction in non-
pregnant participants. In non-pregnant obese participants, a
comprehensive programme of lifestyle modification indu-
ces a mean weight loss of 7–10%(43).
In pregnancy, there are currently several clinical trials
ongoing which are evaluating the use of a complex inter-
vention to improve pregnancy outcome in obese women.
To date, evidence is conflicting about the effectiveness of
such interventions in pregnancy. A recent systematic
review assessed the role of complex interventions in lim-
iting gestational weight gain or reducing the risk of mac-
rosomia(11). There was significant heterogeneity across the
studies related to the intensity of the intervention provided,
ranging from additional dietetic sessions at each antenatal
visit(44,45) to a single dietetic visit at the start of preg-
nancy(46), making direct comparisons between studies
difficult. However, the review found no statistically sig-
nificant differences between women who received the
antenatal intervention and those who did not for mean
gestational weight gain (four studies; 416 women; weigh-
ted mean difference 3.10 kg; 95% CI 8.32, 2.13 (random
effects model)) or large-for-gestational-age infant outcome
(three studies; 366 women; risk ratio 2.02; 95% CI 0.84,
4.86), and concluded that there is currently ‘Little high
quality evidence available from randomised controlled
trials to guide practitioners of the effect of limiting gesta-
tional weight gain in terms of important maternal and
infant health outcomes’.
Drug interventions
Weight-loss drugs are recommended as an adjunct to life-
style intervention in non-pregnant participants who are
unable to loose sufficient weight using a combination of
exercise and diet alone(39). Currently only sibutramine
(a selective serotonin and norepinephrine reuptake inhi-
bitor, which acts centrally to reduce food intake) and
orlistat (a pancreatic lipase inhibitor) are licensed for long-
term weight loss by the Food and Drug Administration in
the USA. In Europe, only orlistat is licensed for weight
loss. Neither of the drugs is licensed for use in pregnancy,
and their use is, therefore, not recommended as an adjunct
to lifestyle intervention to promote weight reduction or
maintenance in pregnancy.
Pharmacotherapy may have some benefits if used in a
targeted approach to reduce the risk of specific complica-
tions, which are increased with obesity, such as pre-
eclampsia. Low dose of the antiplatelet aspirin is of mild to
moderate benefit in the prevention of pre-eclampsia in
women at high risk of developing the disease(47). However,
‘moderate risk factors’ are ill defined and data for the
benefits of aspirin in obese women are lacking. Despite
this, it is the opinion of the National Institute for Health
and Clinical Excellence guideline development group in
the UK that women with more than one moderate risk
factor, which potentially includes obesity, may benefit
from 75 mg aspirin from 12 weeks gestation(48).
Bariatric/surgical interventions
In the USA, the incidence of bariatric surgery has
increased by 800% from 1998 to 2005, with more than
50 000 women aged 18–45 currently having bariatric sur-
gery per annum(49). The rate of bariatric surgery is simi-
larly increasing in other developed countries(50). A wide
range of different surgical procedures are performed
including laparoscopic adjustable gastric banding, vertical-
banded gastroplasty, Roux-en-Y gastric bypass (gastric
bypass) and biliopancreatic diversion/duodenal switch,
with laparoscopic adjustable gastric banding being the
most commonly performed procedure.
A systematic review by Maggard et al.(49) evaluated the
effect of bariatric surgery on pregnancy outcomes. To date,
there are no randomised controlled trials comparing preg-
nancy outcome after bariatric surgery. Current evidence
is, therefore, dependent on observational cohort or case–
control studies, and case reports. Matched cohort studies
demonstrated that the rates of maternal complications were
substantially lower in obese women after bariatric surgery
when compared to obese women without bariatric surgery,
and approached rates found in non-obese controls.
One cohort study that compared rates of complications in
thirteen consecutive deliveries following laparoscopic





















Table 2. Level of evidence for antenatal care strategies
Strategy Level of evidence*
Specialist antenatal care(21) 4
Pre-pregnancy weight optimisation(54), 4
Ultrasound(56–58) 2 +
Screening for gestational diabetes(67,68) 2 + +
Screening for pre-eclampsia(69) 2 + +
Thromboprophylaxis(63) 2 + +
Anaesthetic review(21) 3
*See Table 3.





















adjustable gastric banding surgery with outcomes of 414
consecutive patients who were obese (BMI ‡ 30 kg/m2)
who delivered at the same practice between 2004 and 2006
found a significant reduction in rates of pre-eclampsia (0%
v. 3.1%, P<0.05) and gestational diabetes (0% v. 22.1%,
P<0.05)(51). Neonatal outcomes were similarly better after
laparoscopic adjustable gastric banding surgery (7.7% v.
14.6% for macrosomia, 7.7% v. 10.6% for low birth
weight and 7.7% v. 7.1% for premature delivery; all
P<0.05). However, when gastric bypass was compared to
non-obese controls, the studies are conflicting regarding
maternal outcomes and there were no differences in neo-
natal outcomes for premature delivery, low birth weight
and macrosomia. Currently, evidence is insufficient to
assess the effect of bariatric surgery on mode of delivery,
nutritional status and fertility. Similarly, there are few data
available to inform timing of surgery with respect to
pregnancy, with successful pregnancies being achieved
within 1–2 years of the procedure. Finally, bariatric sur-
gery is not without its complications, which can include
bowel obstruction, preterm delivery and ultimately mater-
nal and fetal death(52).
Incentives and social marketing
Incentives are effective in effecting simple, time-limited
behavioural change, for example attending hospital
appointments(53). Offering financial or other incentives to
encourage lifestyle modification is becoming increasingly
common for promoting complex behavioural change,
including weight reduction. However, despite their rising
popularity, there is a paucity of high-quality evidence
about the effectiveness of such interventions, their
mechanisms of action, and effects at an individual or
societal level. Hence the type, level and mode of delivery
of incentivisation are essentially arbitrary. Whether incen-
tives have a role in improving pregnancy outcome in obese
women is not known.
A summary of all the intervention strategies discussed is
illustrated in Table 1. The level of evidence (defined in
Table 3) to support these strategies is also shown, high-
lighting the relative lack of good quality evidence currently
available.
Antenatal care
In the absence of an intervention(s) proven to improve
pregnancy outcome in obese women, clinicians are left
with optimising maternal health pre-pregnancy and pro-
viding appropriate high-risk (often non evidence-based)
antenatal care for obese pregnant women.
Pre-pregnancy, obese women planning a pregnancy
should be given the opportunity to optimise their weight
and treatment of common conditions associated with
maternal obesity such as essential hypertension. Losing
5–10% of their body weight prior to conception has sig-
nificant health benefits(54), and rationalising drug therapy
can reduce the risk of drug-induced teratogenicity(55).
Once pregnant, obese women should be recognised as a
high-risk group and should be referred for appropriate
antenatal care(5). Ultrasound is widely used for pregnancy
dating, detection of fetal anomalies and assessment of fetal
growth. However, ultrasound assessment is less accurate in
obese women(56). Women should, therefore, be informed
about the reduced sensitivity of ultrasound with increasing
maternal size(57,58). To ensure accurate diagnosis of
hypertensive complications of pregnancy including pre-
eclampsia and pregnancy-induced hypertension, it is
important to use appropriate sized blood pressure cuffs.
Too small a cuff will overestimate blood pressure, too large
a cuff is associated with less error(59). Gestational and pre-
existing diabetes are also more common in obese women.
While there is no debate that appropriate treatment of
diabetes (pre-existing or gestational) in pregnancy sig-
nificantly reduces the risk of serious adverse perinatal out-
come (e.g. death, shoulder dystocia, bone fracture and
nerve palsy)(60), there is no consensus about how and when
to screen for gestational diabetes, and what diagnostic cri-
teria should be used. Once gestational diabetes has been
diagnosed, glycaemic control should be optimised using
dietary modification first, and if that is insufficient, then the
oral hypoglycaemic drug metformin(61) or insulin should be
used.
The antenatal period is also a time of increased
thrombotic risk, particularly for obese women(62) with
thromboembolism remaining a leading cause of maternal
mortality worldwide. To reduce the risk of thromboembo-
lism, low molecular weight heparins are used, dependent
on a risk-based scoring system for antenatal thrombopro-
phylaxis. The Royal College of Obstetricians and Gynae-
cologists in the UK recommends that antenatal
thromboprophylaxis with low molecular weight heparin be
considered for any woman who has a BMI greater than
30 kg/m2 plus two or more additional risk factors and
this should commence as early as practically possible in
Table 3. Levels of evidence
Level Evidence
1 + + High-quality meta-analyses, systematic reviews of randomised controlled trials (RCT) or RCT with very low risk of bias
1 + Well-conducted meta-analyses, systematic reviews of RCT or RCT with a low risk of bias
1 - Meta-analyses, systematic reviews of RCT or RCT with a high risk of bias
2 + + High-quality systematic reviews of case-control or cohort studies or high-quality case-control or cohort studies with a very low risk
of confounding, bias or chance and high probability that the relationship is causal
2 + Well conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the
relationship is causal
2 - Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal
3 Non-analytical studies, e.g. case reports, case series
4 Expert opinion/formal consensus





















pregnancy(63). Similar scoring systems are recommended
for use in the USA. The optimal dose of low molecular
weight heparin required to achieve effective thrombopro-
phylaxis in lean and obese women, however, remains to be
established in clinical trials(64).
Maternal obesity poses particular risks at the time of
delivery with the risks of instrumental delivery, caesarean
section, shoulder dystocia and postpartum haemorrhage all
being increased with maternal BMI(3). Anaesthetic proce-
dures such as siting an epidural or spinal anaesthetic and
performing a general anaesthetic are also more difficult
with maternal obesity. It is, therefore, helpful if women,
particularly those with Class III obesity (BMI>40 kg/m2),
are reviewed by an anaesthetist antenatally and deliver in a
medically led delivery suite so that intrapartum problems
can be recognised early and managed appropriately with
staff who have experience in managing the care of these
high-risk women intrapartum.
Table 2 provides a summary of the antenatal care stra-
tegies discussed and the level of evidence (defined in
Table 3) currently available upon which these strategies
are based.
Summary
The global pandemic presents a major challenge for
healthcare providers, and has significant short- and long-
term implications for both maternal and fetal health. At
present, the evidence-base underpinning many of the
interventions either currently in use or recommended to
improve pregnancy outcome in obese women is limited.
Until the outcomes of ongoing current trials are reported
and provide firm evidence base on which to base future
intervention strategies and guide evidence-based care for
obese pregnant women, pregnancy outcome is best opti-
mised by high-risk antenatal care delivered by healthcare
providers who are experienced in supporting these high-
risk women.
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